Accropeutics has developed a robust portfolio of innovative compounds spanning from lead optimization to clinical trials. The company's RIPK1 inhibitor AC-003 has completed the Phase I clinical trial in China and the United States in August 2023 and achieved positive results, and the clinical trial for aGvHD patients is currently undergoing. The Company's RlPK2 inhibitor AC-101 has completed the Phase I clinical trial in Australia demonstrating an outstanding safety and PK/PD profile. AC-201, a selective TYK2/JAK1 inhibitor with "Pipeline-in-a-Product" potential for treating inflammatory and autoimmune diseases, has completed the Phase I trial in Australia and China, and is currently in Phase II clinical trial for patients with moderate to severe plaque psoriasis. The Company has multiple compounds in the PCC and preclinical research stages. The Company owns global rights of all its assets with more than 10 patents issued in major markets including the US, the EU, China, Japan, and Korea.
Dr. Henri Nico Doods was Senior Vice President of Boehringer Ingelheim and Global Head of Boehringer Ingelheim Research Beyond Border.
Dr. Doods has nearly 30 years of experience in pharmaceutical research and development, covering cardiovascular, pain, obesity, neurological, respiratory and other fields. He published more than 135 papers, and advanced more than 15 compounds into clinical development, including nintedanib (Ofev), the standard of care for the treatment of IPF. He received a Ph.D. degree is from University of Amsterdam.
AC-101 First in Patient in Phase Ib for UC in China
AC-101 MRCT Phase II for UC was Approved by FDA
AC-201 Phase II clinical trial for NIU was approved by NMPA
AC-201 First in Patient in China for Phase II in Psoriasis
AC-003 First in Patient in China for Phase Ib in aGVHD
AC-101 clinical trial was approved (HREC)
AC-101 first in human in AUS
AC-003 clinical trial for GVHD was approved (NMPA)
AC-101 IND Approval (NMPA)
AC-201 first in human in AUS
AC-201 IND Approval (NMPA)
AC-201 first in human in China
AC-003 has been granted ODD by the FDA
AC-003 first in human in the US
AC-003 IND Approval (NMPA)
AC-003 first in human in China
Series B Financing
AC-003 IND Approval (FDA)
Series A Financing
Found Accro Bioscience (Suzhou) Limited
For investor relations related matters, please contact us at info@accropeutics.com
